EcoDrugPlus

Cholesterol 24-Hydroxylase

Ensembl ID : ENSMOCG00000018091
Gene Symbol: LOC101999920
3 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSMOCG00000002497
Gene Symbol: CHRM1
3 Cross references
101 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSMOCG00000007177
Gene Symbol: CHRM2
3 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSMOCG00000005385
Gene Symbol: CHRM3
3 Cross references
255 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSMOCG00000016103
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSMOCG00000010076
Gene Symbol: CHRM5
3 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSMOCG00000008067
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSMOCG00000004769
Gene Symbol: CHRNA4
2 Cross references
203 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSMOCG00000008300
Gene Symbol: CHRNA7
3 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSMOCG00000020688
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSMOCG00000019629
Gene Symbol: CHRNB4
3 Cross references
198 Possible Orthologues:

Churchill Domain Containing 1

Ensembl ID : ENSMOCG00000017411
Gene Symbol: CHURC1
3 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).